| Project/Area Number |
25290054
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor diagnostics
|
|---|
| Research Institution | National Institutes of Biomedical Innovation, Health and Nutrition |
|---|
Principal Investigator |
Tomonaga Takeshi 国立研究開発法人医薬基盤・健康・栄養研究所, プロテオームリサーチプロジェクト, プロジェクトリーダー (80227644)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ISHIHAMA Yasushi 京都大学, 薬学部, 教授 (30439244)
MATSUBARA Hisahiro 千葉大学, 医学研究院, 教授 (20282486)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
NAGAYAMA Satoshi 公益財団法人がん研究会, 有明病院消化器外科, 医長 (70362499)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥16,770,000 (Direct Cost: ¥12,900,000、Indirect Cost: ¥3,870,000)
Fiscal Year 2015: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2014: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2013: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
|
|---|
| Keywords | リン酸化プロテオミクス / 薬効予測 / EGFR阻害剤 / 肺がん / プロテオミクス / バイオマーカー / リン酸化タンパク質 / がん / リン酸化タンパク |
|---|
| Outline of Final Research Achievements |
Molecular target drugs such as kinase inhibitors for cancer treatment are not uniformly clinically effective, thus sorting the patients that will benefit from the treatments is critical. Moreover, acquired resistance for the drugs is also a critical problem. Therefore, the identification of mechanisms underlying the resistance is urgent need. Systematic quantification of kinase activation is potentially predictive of the response of kinase inhibitors and it can be quantitated by phosphorylation level of their substrates. In this study, we developed a large-scale phosphoproteome quantification method for the kinase substrates and applied for prediction of the kinase activities and drug response. We also examined the mechanism of drug resistance. By the phosphoproteome analysis of several lung cancer cell lines which are sensitive or resistant for the drug currently used in clinic, erlotinib, we identified several phosphoproteins and kinases which are able to predict drug sensitivity.
|
